Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Neuroleptic or Opioid or PDE5 Inhibitor

Use the filters below to narrow your results.

generic:
Codeine (2)
brand:
None (12)
classes: (Click arrow to add another value)
mechanism:
Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Phenothiazine D2 antagonist (4)
uses:
None (47) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000040-QINU`"' (1) · '"`UNIQ--vote-00000669-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) · '"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1)
starting dose:
None (47) · 10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) · 10 mg ~1 h before sexual activity (1) · 100 mg ~15 min before sexual activity (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) · Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
None (47) · 2.5, 5, 10, 20 mg tabs (1) · 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · 50, 100, 200 mg tabs (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (47) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 20 mg/d (1) · 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) · 200 mg/d (100 mg/d if on CYP3A4 inhibitors) (1) · 360 mg/day (1)
routes:
None (47) · IV (Revatio) (1) · Oral (4) · PO (only formulation marketed in the US). (1)
onset:
None (47) · 30 min (1) · 30–60 min (1) · 30–60 min (PO) (1) · ~15 min (fastest of the PDE5 inhibitors) (1) · ~30 min (1)
duration:
None (47) · 4–5 h (1) · 4–6 h (1) · 4–6 hours (1) · Up to 36 h ("the weekend pill") (1) · ~4 h (1)
halflife:
None (47) · 2.5–3 hours (1) · 4–5 h (1) · ~17.5 h (1) · ~4 h (1) · ~5 h (1)
bioavailability:
None (47) · Rapid absorption; absolute bioavailability not formally established (1) · Reasonable (not formally established as a percentage) (1) · ~15% (extensive hepatic first-pass) (1) · ~40% (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (47) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category B (3) · Category C (not relevant; not used in women) (1)
legal:
None (47) · Rx-only in US (4) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 52 results in range #1 to #52.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"